Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing.

Circulation research - 15 Aug 2014

Ding Qiurong, Strong Alanna, Patel Kevin M, Ng Sze-Ling, Gosis Bridget S, Regan Stephanie N, Cowan Chad A, Rader Daniel J, Musunuru Kiran

Abstract excerpt

RATIONALE: Individuals with naturally occurring loss-of-function proprotein convertase subtilisin/kexin type 9 (PCSK9) mutations experience reduced low-density lipoprotein cholesterol levels and protection against cardiovascular disease. OBJECTIVE: The goal of this study was to assess whether gen...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 3T3-L1 Cells
Share to Adenoviridae
Share to Clustered Regularly Interspaced Short Palindromic Repeats

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proprotein Convertase 9

Share to Proprotein Convertases

Share to Protective Factors

Share to RNA Editing

Share to RNA, Guide, CRISPR-Cas Systems

Source

Open in PubMed Open full text

Identifiers

PMID: 24916110
DOI: 10.1161/CIRCRESAHA.115.304351
PMCID: PMC4134749

Genes

PCSK9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24916110-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing.PMID 24916110Read ↗

CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo-Brief Report.Semantic proximity Read ↗

Is It Ever Wise to Edit Wild-Type Alleles? Engineered CRISPR Alleles Versus Millions of Years of Human Evolution.Semantic proximity Read ↗

CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and OpportunitiesSemantic proximity Read ↗

CRISPR-Cas9 Targeting PCSK9: A Promising Therapeutic Approach for Atherosclerosis.Semantic proximity Read ↗

Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.Semantic proximity Read ↗

Long-term stable reduction of low-density lipoprotein in nonhuman primates following in vivo genome editing of PCSK9Semantic proximity Read ↗

In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing.Semantic proximity Read ↗

Silencing hepatic PCSK9 via novel chimeric AAV8 mitigates the progression of atherosclerosis by inhibiting inflammation in ApoE−/− miceSemantic proximity Read ↗

Gene Editing for the Treatment of HypercholesterolemiaSemantic proximity Read ↗

CRISPR-Cas12a delivery by DNA-mediated bioresponsive editing for cholesterol regulationSemantic proximity Read ↗

PCSK9: a key modulator of cardiovascular health.Semantic proximity Read ↗

A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivoSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.